Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising ...
Atopic Dermatitis Affects Millions, And Johnson & Johnson Is Committed To Addressing The Unmet Needs Of Patients
AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...
Johnson & Johnson price target raised to $166 from $159 at Barclays
Barclays raised the firm’s price target on Johnson & Johnson to $166 from $159 and keeps an Equal Weight rating on the shares. The company ...